Abstract:
A dry powder formulation for mucosal, intranasal, inhalation or pulmonary delivery which may include one or more siRNAs or dicer-active precursors thereof targeted to a transcript involved in infection by, or replication or production of an influenza virus.
Abstract:
Spray dried particles having specified aerodynamic characteristics are produced by atomizing a liquid feed and contacting the liquid feed with a drying gas, such as, for example, air or nitrogen. The humidity of the drying gas is controlled to a value, expressed, for instance, as dew point, which is known to produce particles having a specified tap density or aerodynamic diameter. Particles having a volume median geometric diameter greater than about 5 microns and a tap density less than about 0.4 g/cm3 are preferred.
Abstract translation:通过雾化液体进料并使液体进料与例如空气或氮气的干燥气体接触来产生具有特定空气动力特性的喷雾干燥颗粒。 干燥气体的湿度被控制为例如表示为露点,其已知产生具有特定振实密度或空气动力学直径的颗粒。 体积中值几何直径大于约5微米且振实密度小于约0.4g / cm 3的颗粒是优选的。
Abstract:
Air-hardenable steels of duplex bainite/martensite microstructure consisting essentially of 0.10 to 0.7% C, 0.1 to 2% Si, 2.1 to 3.5% Mn, 0.0005 to 0.005% B, up to 3.5% Cr and preferably containing Cr in amount of at least 0.1%, balance Fe except for incidental impurities. Optional elements are up to 1.5% W, 1.0% Mo, 0.15% V, 0.2% S, 0.1% Ca, 0.1% Pb, 0.1% Ti and 0.2% total rare earths. At least 1.0% Cr is especially preferred and if below such amount, total Mn and Si is at least 3% and in such case, if C is under 0.47%, at least 0.6% Si is present. The steels are hardenable to R.sub.c 2o to R.sub.c 58 and have a hardenable diameter in the range between 35 mm and 80 to 100 mm by air-cooling only, together with good strength, toughness and fatigue- and wear-resistance.
Abstract:
A dry powder formulation for delivery to a mammal by inhalation, the formulation comprising particles comprising a lipid, a carrier, and one or more double-stranded siRNA molecules or dicer-active precursors targeted to influenza virus A method for treating or preventing influenza in a mammal comprising administering a therapeutically-effective amount of a dry powder formulation.
Abstract:
Spray dried particles having specified aerodynamic characteristics are produced by atomizing a liquid feed and contacting the liquid feed with a drying gas, such as, for example, air or nitrogen. The humidity of the drying gas is controlled to a value, expressed, for instance, as dew point, which is known to produce particles having a specified tap density or aerodynamic diameter. Particles having a volume median geometric diameter greater than about 5 microns and a tap density less than about 0.4 g/cm3 are preferred.
Abstract:
Air-hardenable steels of duplex bainite/martensite microstructure consisting essentially of 0.10 to 0.7% C, 0.1 to 2% Si, 2.1 to 3.5% Mn, 0.0005 to 0.005% B, up to 3.5% Cr and preferably containing Cr in amount of at least 0.1%, balance Fe except for incidental impurities. Optional elements are up to 1.5% W, 1.0% Mo, 0.15% V, 0.2% S, 0.1% Ca, 0.1% Pb, 0.1% Ti and 0.2% total rare earths. At least 1.0% Cr is especially preferred and if below such amount, total Mn and Si is at least 3% and in such case, if C is under 0.47%, at least 0.6% Si is present. The steels are hardenable to R.sub.c 20 to R.sub.c 58 and have a hardenable diameter in the range between 35 mm and 80 to 100 mm by air-cooling only, together with good strength, toughness and fatigue- and wear-resistance.
Abstract:
Spray dried particles having specified aerodynamic characteristics are produced by atomizing a liquid feed and contacting the liquid feed with a drying gas, such as, for example, air or nitrogen. The humidity of the drying gas is controlled to a value, expressed, for instance, as dew point, which is known to produce particles having a specified tap density or aerodynamic diameter. Particles having a volume median geometric diameter greater than about 5 microns and a tap density less than about 0.4 g/cm3 are preferred.
Abstract translation:通过雾化液体进料并使液体进料与例如空气或氮气的干燥气体接触来产生具有特定空气动力特性的喷雾干燥颗粒。 干燥气体的湿度被控制为例如表示为露点,其已知产生具有特定振实密度或空气动力学直径的颗粒。 体积中值几何直径大于约5微米且振实密度小于约0.4g / cm 3的颗粒是优选的。
Abstract:
The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.
Abstract:
The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion.
Abstract:
The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion.